RxDoctor Payments Data

Daniel Brody, DO

Cardiovascular Disease · Grand Rapids, MNNPI 1174753313

Payments from drug & device makers

$6,011in general payments, 2019–2025

Across 55 payments — averaging $109.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$3K
  • Medtronic$2K
  • Heartflow, Inc.$530
  • Abbott$169
  • Scpharmaceuticals Inc.$75
  • E.r. Squibb & Sons, L.L.C.$64
  • plus $135 from 5 others

What the payments were for

  • Travel & lodging$3,71762%
  • Food & beverage$2,29438%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,011 in reported general payments places this provider in the 60th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$33,991
Medicare patients
387
Services billed
747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban447$482,447
EntrestoSacubitril/Valsartan229$305,745
JardianceEmpagliflozin138$159,426
FarxigaDapagliflozin Propanediol116$117,984
XareltoRivaroxaban92$102,697
BrilintaTicagrelor27$24,292
Metoprolol Succinate613$12,430
Rosuvastatin Calcium405$8,033
Digoxin34$6,123
Atorvastatin Calcium393$5,867
Losartan Potassium336$3,699
Flecainide Acetate39$3,548
Torsemide133$3,274
Isosorbide Mononitrate ErIsosorbide Mononitrate137$2,871
Diltiazem 24hr ErDiltiazem Hcl64$2,679

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$16$305,745229 claims
AstraZenecaFarxiga, Brilinta$23$142,276143 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Grand Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →